TQB2928 plus third-generation EGFR TKI for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called TQB2928 combined with a common targeted therapy (a third-generation EGFR TKI) for people with advanced non-small cell lung cancer. The goal is to see if this combination is safe and effective, especially for those whose cancer has progressed after previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced non-small cell lung cancer that has spread or cannot be removed by surgery.
- You should be in relatively good health, able to take care of yourself, and expected to live at least 3 more months.
- Your major organs (like heart, liver, kidneys) must be working well enough.
- If you could become pregnant, you must have a negative pregnancy test and agree to use birth control during the study and for 6 months after.
- You cannot have had another cancer in the last 5 years, or have any serious ongoing health problems that are not controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
This trial tests a new injection called TQB2922 for people with advanced non-squamous non-small cell lung cancer who have already tried standard treatments. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
This trial tests an experimental oral drug called TQB3002 for people with advanced solid tumors who have run out of standard options. Researchers are learning the best dose and how safe it is, with the hope of controlling or shrinking the cancer.
This trial tests an experimental drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to understand how the body handles the drug and what side effects may occur. It may be an option if your tumor has a specific marker called ROR1.
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
Hear when a new Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.